Insulin B-chain-specific T-cell receptor (null)

The Insulin B-specific T-cell receptor is a heterodimeric transmembrane receptor expressed on the surface of T lymphocytes that enables recognition of insulin B-chain–derived peptides presented by MHC molecules (such as HLA-DQ8 or mouse I-Ag7)[3][5][9][10]. These TCRs use variable gene segments conferring specificity for insulin epitopes; for example, the B:9-23 or B:11-23 region, which contains critical residues for TCR contact and overall antigenicity[3][4][9]. Recognition of these epitopes initiates T-cell activation, cytokine secretion (notably IFN-γ), and immune effector functions that contribute directly to the destruction of pancreatic β-cells in type 1 diabetes[3][5][9][10]. Studies have defined structural and sequence features underlying antigen recognition, including register-dependent presentation, V-gene usage, and the impact of key contact residues on TCR affinity and pathogenicity[3][5][9][10]. \n\nThis target is under intense research for both diagnostic and therapeutic purposes in autoimmune diabetes, with attempts to characterize the unique TCR clonotypes driving autoimmunity and to develop antigen-specific tolerizing interventions[2][9][10].

Other names

insulin B:9-23-specific T-cell receptorinsulin B:11-23-specific T-cell receptorinsulin B-chain TCRinsulin-specific T-cell receptor

Drugs or therapies that act on insulin B-specific T cells aim to induce immune tolerance (e.g., tolerogenic peptide vaccines), modulate T-cell activation, or selectively deplete pathogenic T cells